Clinical Trial Update: AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update showing completion and posted results for AZD0530 (saracatinib) in extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AZD0530 (saracatinib) (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Lung Metastases | Phase 2 | Status: COMPLETED | Results posted: 2014-02-11